Elena A. Kovalevskaya

Elena A. Kovalevskaya

Auto-generated profile, based on publicly available information

Elena A. Kovalevskaya

Pirogov Russian National Research Medical University (Pirogov University); Moscow Clinical Science and Research Center 52

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
NPN. G. Poteshkina
N. G. Poteshkina
MLM. A. Lysenko
M. A. Lysenko
EKE. A. Kovalevskaya
E. A. Kovalevskaya
DFD. S. Fomina
D. S. Fomina
ISI. V. Samsonova
I. V. Samsonova
ОЕО. Ю. Евсюков
О. Ю. Евсюков
The article reviews studies that confirm the relationship of a negative prognosis with the presence of risk factors for cardiovascular complications during respiratory infections, including novel coronavirus infection COVID-19. The article presents the relevant research results that provide evidence on the myocardial damage in coronavirus infection. We present a clinical case of a patient with confirmed diagnosis of COVID-19 and severe viral myocarditis, verified by histological and immunohistochemical studies.

21 June 2020 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
DFD. S. Fomina
D. S. Fomina
NPN. G. Poteshkina
N. G. Poteshkina
IBI. P. Beloglazova
I. P. Beloglazova
ZMZ. Yu. Mutovina
Z. Yu. Mutovina
ISI. V. Samsonova
I. V. Samsonova
ДКД. Б. Крлыкова
Д. Б. Крлыкова
According to accumulated clinical data, one of the causes of severe damage to lung epithelial cells associated with SARS-CoV-2 (2019-nCoV) is an acute, timely underestimated "cytokine storm" (cytokine cascade, hypercytokinaemia) with characteristic signs of an expressed hyper-inflammatory syndrome with subsequent polyorganic failure. The study presents the results of the analysis of the effectiveness of tocilizumab therapy (TCZ) in patients (n = 181) of different age groups with developed pneumonia caused by SARS-CoV-2. The aim of the study was to evaluate the effectiveness of TCZ therapy in patients of different age groups with developed pneumonia in the frame of COVID-19. Methods. Patients (n = 181) with community-acquired pneumonia caused by coronavirus SARS-CoV-2 are included in a one-center, non-randomized, prospective study to evaluate the effectiveness of TCZ therapy conducted at the State Public Health Institution "City Clinical Hospital No.52" of the Moscow City Health Department. Patients were divided into 3 age subgroups – up to 50 years, 50–70 years and over 70 years. Patients with community-acquired SARS-CoV-2-induced pneumonia receiving non-invasive oxygen support and patients who had artificial lung ventilation (ALV) were given a single dose of 400 mg of TCZ in addition to basic therapy. Results. There are no significant differences between age groups in the severity of pneumonia according to the data of the computed tomography (CT), however, a more severe condition and a higher mortality rate (p < 0.001) were reliably observed in patients over 70 age compared to the other age groups. After TCZ treatment in patients of each age group, the severity of the condition assessed on the National Early Warning Score (NEWS2) has been significantly reduced compared to the baseline. Conclusion. According to the data of the pilot study the efficacy and safety of TCZ in patients of all presented age groups with COVID-associated pulmonary tissue lesion and signs of "cytokine storm" was demonstrated. At the same time, patients up to 50 years after the therapy of TCZ managed to achieve greater clinical efficiency compared to patients in other groups. According to the severity of the state and laboratory criteria, the lowest clinical efficacy of TCZ therapy was observed in patients over 70 years of age; as a consequence, the highest mortality rate was observed in the same group. At the same time, the TCZ therapy has not had a positive impact on the change of laboratory values and the severity of the disease in case of unfavorable outcome.

15 November 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
TKTatyana S. Kruglova
Tatyana S. Kruglova
DFDarya S. Fomina
Darya S. Fomina
NPNataliуa G. Poteshkina
Nataliуa G. Poteshkina
NFNadija F. Frolova
Nadija F. Frolova
IBIrina P. Beloglazova
Irina P. Beloglazova
САСердотецкова Софья Александровна
Сердотецкова Софья Александровна
Aim. To determine the criteria for the optimal use of IL-6 receptor blockers in patients with COVID-19 community-acquired pneumonia based on predictors of adverse outcomes. Materials and methods. The single-center, non-randomized prospective study included 190 patients with community-acquired pneumonia caused by coronavirus 2 between the beginning of March and the end of May 2020. Of these, 89 patients received tocilizumab and 101 patients received sarilumab. The study inclusion criterion for the patient was indications for initiating therapy with one of the inhibitors of IL-6 receptors (anti-IL-6R) according to the Interim guidelines (versions 4 and 5). The exclusion criterion was the need to re-prescribe genetically engineered biological therapy (GEBT). The severity of the patient's condition was assessed according to the early warning score (NEWS2), the volume of lung tissue lesions was assessed according to computed tomography (CT). Laboratory monitoring included counting the absolute (abs) number of lymphocytes, serum levels of C-reactive protein (CRP), interleukin 6 (IL-6), D-dimer, lactate dehydrogenase, fibrinogen. Statistical data processing was conducted by nonparametric methods using the IBM SPSS Statistics V-22 software. Results. The phenotype of a patient with a negative outcome prognosis was described: a male patient over 50 years of age with aggravated premorbid background (with cardiovascular diseases, obesity and/or chronic renal disease), lung lesion CT 34, saturation less than 93% upon inhalation of atmospheric air, persisting for 2448 hours after GEBT. According to the blood test, lymphopenia was below 1000 U/L and CRP levels were above 50 mg/L. The laboratory parameters and clinical picture of the patient progressively worsened after 911 days of illness, regardless of the use of Anti-IL-6R. The features of patients monitoring when administering IL-6 receptor blockers have been determined. Conclusion. IL-6 receptor blockers should be administered to patients hospitalized with severe COVID-19 before the development of hyperinflammatory reactions. The optimal "therapeutic window" is 78 days of illness.

25 October 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
NPN. G. Poteshkina
N. G. Poteshkina
NKN. S. Krylova
N. S. Krylova
AKA. A. Karasev
A. A. Karasev
TNT. A. Nikitina
T. A. Nikitina
ASA. M. Svanadze
A. M. Svanadze
VSV. N. Smorshchok
V. N. Smorshchok
Aim. To assess right heart condition in patients with coronavirus disease 2019 (COVID-19) pneumonia.Material and methods. One hundred and five patients with COVID-19 pneumonia were divided into 3 groups depending on the involvement of lung parenchyma: group I — 0-25%, II — 25-50%, III — 50-75%. The clinical status of patients was assessed using the NEWS2 and SHOKS-COVID scales. A complete blood count and biochemical blood tests were performed to determine the level of N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin I. Echocardiography was performed to assess the right heart structural, hemodynamic and functional parameters.Results. In patients with COVID-19 pneumonia, with an increase in lung parenchyma involvement, the intensity of systemic inflammatory response increased: C-reactive protein, group I — (4 [1,9; 35] mg/l), in III — (70,5 [33; 144] mg/l) (pI-III=0,012); myocardial stress marker level increased: NT-proBNP, group I — 77 [48; 150] ng/l, group III — 165 [100; 287] ng/l (pI-III=0,047). The dependence of NT-proBNP on C-reactive protein level was revealed (r=0,335, p=0,03). Intergroup comparison did not reveal significant differences between the main right heart functional parameters: TAPSE, Tei index (PW and TDI), FAC of the right ventricle (RV) (p>0,05). However, differences in the tricuspid annular peaks were found as follows: group I — 0,14 [0,12; 0,14] m/s, group II — 0,14 [0,12; 0,15] m/s, group III — 0,16 [0,14; 0,17] m/s (pI-II=0,012, pI-III=0,014) and RV global longitudinal strain: group I — 19,63±7,72%, group III — 27,4±5,93% (pI-III=0,014). The relationship between the RV global longitudinal strain and SHOKS-COVID score was confirmed (r=0,381; p=0,024).Conclusion. Patients with COVID-19 pneumonia showed no signs of right heart dysfunction. The development of RV hyperfunction was noted. Most likely, this is a compensatory mechanism in response to acute RV afterload. NT-proBNP increase under conditions of an inflammatory response may indicate myocardial stress. The results obtained allow to expand our understanding of the right heart condition in patients with COVID-19 pneumonia.

24 March 2023 in Molecular Genetics Microbiology and Virology (Russian version)
Verified
Journal Article
Closed access
AKAnna Klass
Anna Klass
NKN.S. Krylova
N.S. Krylova
ALA.V. Lysenko
A.V. Lysenko
IVIvan Vlasov
Ivan Vlasov
MMM.YU. Maslova
M.YU. Maslova
EFElena Filatova
Elena Filatova
Introduction. Hypertrophic cardiomyopathy (HCM) is considered the most common hereditary heart disease. HCM is a highly heterogeneous disease from a genetic point of view. However, despite the large number of identified pathogenic variants, the cause of the disease remains unclear in more than a quarter of patients. Therefore, it is still relevant to study the prevalence of pathogenic variants leading to the development of HCM, especially in the Russian population. In this regard, the aim of this work was to assess the contribution of pathogenic variants rs200411226 and rs397515905 in the MYBPC3 gene, leading to the substitutions R495Q, R495W, and R495G, to the development of HCM in the Russian population. Material and methods. The sample included 224 patients with HCM of varying severity. The genotypes of the rs200411226 (NM_000256.3:c.1484G>A) and rs397515905 (NM_000256.3:c.1483C>T/G) variants in the MYBPC3 gene (R495Q, R495W, and R495G) were analyzed using real-time PCR for all patients. Results and discussion. The analysis of the prevalence of these pathogenic variants carried out in this work has shown that the R495Q and R495W mutations in our sample occur with a frequency of 0.4% for each mutation, which is generally comparable with the frequencies of these pathogenic variants in other populations. In addition, R495Q and R495W mutations do not appear to lead to severe disease. Conclusion. We failed to identify the pathogenic R495G variant in our sample of patients with HCM. Thus, these mutations by themselves do not significantly contribute to the development of HCM in the Russian population.

12 March 2022 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
NPN. G. Poteshkina
N. G. Poteshkina
NKN. S. Krylova
N. S. Krylova
MMM. Y. Maslova
M. Y. Maslova
EKE. A. Kovalevskaya
E. A. Kovalevskaya
ASA. M. Svanadze
A. M. Svanadze
GSG. B. Selivanova
G. B. Selivanova
Aim. To assess the relationship between the level of salt (NaCl) consumption and clinical and hemodynamic parameters in patients with hypertrophic cardiomyopathy (HCM) of different age groups.Material and methods. We examined 57 patients with HCM (mean age, 59,2±16,2 years). The patients were divided into groups according to the World Health Organization (WHO): I — young age (≤44 years old) — 12,4% of patients; II — middle (45-59 years old) — 37,2%; III — elderly (60–74 years old) — 36%; IV — senile (≥75 years old old) — 14,4%. The clinical status of patients was assessed, during which special attention was paid to syncope not related to cardiac arrhythmias. NaCl intake was assessed by the 24-hour urine sodium (Na+) level.Results. In the general cohort, in Na+ level <50 mmol/day, the lowest left ventricular stroke volume (LVSV) index was observed, which were associated with syncope (r=-0,9, p=0,03). With the urinary sodium level of 50-70 mmol/day, an increase in LVSV index was observed and the absence of syncope. At Na+ level more than 70 mmol/day, no increase in LVSV index was observed. In this regard, a predictive model was created, as a result of which it was found that with an increase in Na+ consumption by 1 mmol/day, an increase in LVSV index by 0,3 ml/m2 should be expected. There were no significant differences in the effect of NaCl intake on the studied parameters in patients with HCM of different ages. At the same time, low NaCl intake in elderly patients was associated with syncope.Conclusion. Minimal values of Na+ intake (<50 mmol/day or NaCl 3 g/day) were found, which are unfavorable for patients with HCM due to the risk syncope. The 24-hour urine sodium level to maintain a hemodynamically safe level of LVSV index in patients with HCM should be more than 70 mmol/day (NaCl 4,1 g/day). Monitoring of Na+ consumption level is especially important in elderly people with HCM.